메뉴 건너뛰기




Volumn 26, Issue 12, 2006, Pages 849-853

Pegylation of IFN-α and antiviral activity

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

EID: 33845896277     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.26.849     Document Type: Article
Times cited : (15)

References (22)
  • 1
    • 10744225097 scopus 로고    scopus 로고
    • Global burden of disease (GBD) for hepatitis C
    • The Global Burden of Hepatitis C Working Group
    • The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol. 2004;44:20-29.
    • (2004) J. Clin. Pharmacol , vol.44 , pp. 20-29
  • 2
    • 0033795196 scopus 로고    scopus 로고
    • Interferons: Cell signalling, immune modulation, antiviral response and virus countermeasures
    • Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 2000;81:2341-2364.
    • (2000) J. Gen. Virol , vol.81 , pp. 2341-2364
    • Goodbourn, S.1    Didcock, L.2    Randall, R.E.3
  • 5
    • 0034324083 scopus 로고    scopus 로고
    • Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group
    • Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther. 2000;68:556-567.
    • (2000) Clin. Pharmacol. Ther , vol.68 , pp. 556-567
    • Glue, P.1    Fang, J.W.2    Rouzier-Panis, R.3    Raffanel, C.4    Sabo, R.5    Gupta, S.K.6    Salfi, M.7    Jacobs, S.8
  • 9
    • 0036750664 scopus 로고    scopus 로고
    • Pegylated interferons for the treatment of chronic hepatitis C infection
    • Luxon BA, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin. Ther. 2002;24:1363-1383.
    • (2002) Clin. Ther , vol.24 , pp. 1363-1383
    • Luxon, B.A.1    Grace, M.2    Brassard, D.3    Bordens, R.4
  • 13
    • 0037338922 scopus 로고    scopus 로고
    • Predicting antiviral treatment response in chronic hepatitis C: How accurate and how soon?
    • Lee SS, Abdo AA. Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon? J. Antimicrob. Chemother. 2003;51:487-491.
    • (2003) J. Antimicrob. Chemother , vol.51 , pp. 487-491
    • Lee, S.S.1    Abdo, A.A.2
  • 14
    • 0033045004 scopus 로고    scopus 로고
    • Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein
    • Bowen S, Tare N, Inoue T, Yamasaki M, Okabe M, Horii I, Eliason JF. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp. Hematol. 1999;27:425-432.
    • (1999) Exp. Hematol , vol.27 , pp. 425-432
    • Bowen, S.1    Tare, N.2    Inoue, T.3    Yamasaki, M.4    Okabe, M.5    Horii, I.6    Eliason, J.F.7
  • 15
    • 0036498813 scopus 로고    scopus 로고
    • Biological assays for interferons
    • Meager A. Biological assays for interferons. J. Immunol. Methods 2002;261:21-36.
    • (2002) J. Immunol. Methods , vol.261 , pp. 21-36
    • Meager, A.1
  • 17
    • 0035858379 scopus 로고    scopus 로고
    • Improvements in protein pegylation: Pegylated interferons for treatment of hepatitis C
    • Kozlowski A, Harris JM. Improvements in protein pegylation: pegylated interferons for treatment of hepatitis C. J. Control. Release 2001;72:217-224.
    • (2001) J. Control. Release , vol.72 , pp. 217-224
    • Kozlowski, A.1    Harris, J.M.2
  • 19
    • 0027227660 scopus 로고
    • Structural, functional and evolutionary implications of the three-dimensional crystal structure of murine interferon-beta
    • Mitsui Y, Senda T, Shimazu T, Matsuda S, Utsumi J. Structural, functional and evolutionary implications of the three-dimensional crystal structure of murine interferon-beta. Pharmacol. Ther. 1993;58:93-132.
    • (1993) Pharmacol. Ther , vol.58 , pp. 93-132
    • Mitsui, Y.1    Senda, T.2    Shimazu, T.3    Matsuda, S.4    Utsumi, J.5
  • 20
    • 0036208536 scopus 로고    scopus 로고
    • Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin
    • Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, Esteban R. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002;35:930-936.
    • (2002) Hepatology , vol.35 , pp. 930-936
    • Buti, M.1    Sanchez-Avila, F.2    Lurie, Y.3    Stalgis, C.4    Valdes, A.5    Martell, M.6    Esteban, R.7
  • 22
    • 4344625164 scopus 로고    scopus 로고
    • Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: A randomized, controlled study
    • Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, Filice G. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir. Ther. 2004;9:491-497.
    • (2004) Antivir. Ther , vol.9 , pp. 491-497
    • Bruno, R.1    Sacchi, P.2    Ciappina, V.3    Zochetti, C.4    Patruno, S.5    Maiocchi, L.6    Filice, G.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.